Table 2.
Summary of CAR-T trials in acute lymphoblastic leukemia
| Study center | Patients treated (n) | Median age (range) | No. salvage therapies | Lymphodepleting chemotherapy | CAR-T cell dose | Costimulatory domain | Responses: CR, no. of patients attaining MRD negativity |
|---|---|---|---|---|---|---|---|
| MSKCC55-57 | 44 | 45 (22-74) | 1-3 (median 1), 4 relapsed after allo | Cy first study, then Flu/Cy | 1 × 106/kg vs 3 × 106/kg | CD28 (19-28z) | CR: 37/45 (30/36 MRD-negative) 6 mo OS: 65% |
| FHCRC58 | 29 | 40 (20-73) | 1-11 (median 3) | Cy then Flu/Cy | 2 × 105/kg vs 2 × 106/kg vs 2 × 107/kg | 4-1BB | CR 10/12 in CY group, 14/14 in Flu/Cy group, (23/27 MRD-negative) |
| CHOP53,59 | 53 | 14 (5-60) | 1-4, 3 with primary refractory disease | Investigators choice | 1.07 × 106 to 17.36 × 106 | 4-1BB | CR 50/53 (45/50 MRD-negative) 12 mo OS 78% |
| NCI54 | 20 | 14 (5-27) | 1-8 (median 2), 7 with primary refractory disease | Flu/Cy | 1 × 106/kg vs 3 × 106/kg | CD28 | CR 14/20 (12/14 MRD-negative) 7.8 mo OS 52% |
Cy, cyclphosphamide; Flu, fludarabine.